Pharma Versus Hospitals: 340B Battle Continues
Exploring the continued controversy around the 340B US federal drug discount program. As the story moves into 2022, key questions remain unanswered.
You may also be interested in...
The divide between developed and developing countries for access to health care innovations has been spotlighted by the ongoing COVID-19 pandemic. Civil society groups pile on the pressure.
The race to develop COVID-19 vaccines is intensifying long-standing debate over the ability of lower-income countries to gain affordable access to needed medical treatments. Patient advocates argue that drug makers and wealthy governments are striking deals that place poor countries at a disadvantage. The pharmaceutical industry, however, maintains it is moving as quickly as possible to not only discover safe and effective vaccines, but to enable equitable distribution.
Some believe unmet need refers only to rare diseases and tiny patient populations. But it is more than this. In 2020, the term sits at the heart of decision-making for drug makers – along with cost, access and value, of course.